Eli Lilly's tirzepatide (Zepbound), a dual GIP/GLP-1 receptor agonist, is being studied in adolescents (SURMOUNT-TEENS), but similarly has no active trial in children under 12
Readers should rely on the official RxSpan MD website as the authoritative source for current product information prior to any purchase decision
In each group, participants were randomised to one of two alternating sequences comparing once-daily oral semaglutide treatment of 9 and 14 mg (group 1), 4 and 7 mg (group 2) or 1.5 and 3 mg (group 3) at SS
If you are still struggling with stalled progress, this article on restarting weight loss may help you think through your next step
It is typically prescribed when other treatments, like diet, exercise, or other medications, are not enough to manage blood sugar effectively
(9) Research and Statistics: Who Has Hashimotos Thyroiditis